Nurix Therapeutics, Inc. NRIX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $71.78M-14.5% | $83.98M+0.4% | $83.69M-5.3% | $88.38M+56.7% | $56.42M+3.4% | ||
| $331.38M+4.6% | $316.9M+5.2% | $301.1M+11.3% | $270.46M+12.1% | $241.29M+8.9% | ||
| $55.7M+5.6% | $52.74M+5.9% | $49.81M+3.0% | $48.37M+5.6% | $45.8M-0.3% | ||
| $387.08M+4.7% | $369.65M+5.3% | $350.92M+10.1% | $318.84M+11.1% | $287.09M+7.3% | ||
| -$315.3M-10.4% | -$285.67M-6.9% | -$267.23M-16.0% | -$230.45M+0.1% | -$230.67M-8.3% | ||
| -439.3%-99.1pp | -340.2%-20.8pp | -319.3%-58.6pp | -260.8%+148pp | -408.9%-18.3pp | ||
| -$295.28M-11.7% | -$264.46M-8.0% | -$244.79M-18.1% | -$207.32M+0.5% | -$208.4M-7.7% | ||
| -411.4%-96.5pp | -314.9%-22.4pp | -292.5%-57.9pp | -234.6%+135pp | -369.4%-14.5pp | ||
| -$3.17-3.9% | -$3.05-2.7% | -$2.97-13.8% | -$2.61+6.8% | -$2.80+3.1% | ||
| -$306.71M-10.8% | -$276.93M-7.3% | -$258.06M-16.8% | -$220.92M+0.1% | -$221.05M-8.5% | ||
| -427.3%-97.5pp | -329.8%-21.4pp | -308.4%-58.4pp | -250%+142pp | -391.8%-18.4pp | ||
| -$315.3M-10.4% | -$285.67M-6.9% | -$267.23M-16.0% | -$230.45M+0.1% | -$230.67M-8.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Nurix Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Nurix Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.